APA (7th ed.) Citation

Mujuru, H. A., White, E., Kekitiinwa, A. R., Lugemwa, A., Kityo, C., Violari, A., . . . Cotton, M. (2026). Dolutegravir as First- or Second-line Treatment for Children With HIV: 240-Week Follow-up of the ODYSSEY Randomized Trial. Open Forum Infectious Diseases, 13(5), 1. https://doi.org/10.1093/ofid/ofag266

Chicago Style (17th ed.) Citation

Mujuru, Hilda Angela, et al. "Dolutegravir as First- or Second-line Treatment for Children With HIV: 240-Week Follow-up of the ODYSSEY Randomized Trial." Open Forum Infectious Diseases 13, no. 5 (2026): 1. https://doi.org/10.1093/ofid/ofag266.

MLA (9th ed.) Citation

Mujuru, Hilda Angela, et al. "Dolutegravir as First- or Second-line Treatment for Children With HIV: 240-Week Follow-up of the ODYSSEY Randomized Trial." Open Forum Infectious Diseases, vol. 13, no. 5, 2026, p. 1, https://doi.org/10.1093/ofid/ofag266.